Skip to Content

Generic Invanz Availability

Invanz is a brand name of ertapenem, approved by the FDA in the following formulation(s):

INVANZ (ertapenem sodium - injectable;intramuscular, iv (infusion))

  • Manufacturer: MERCK SHARP DOHME
    Approval date: November 21, 2001
    Strength(s): EQ 1GM BASE/VIAL [RLD]

Has a generic version of Invanz been approved?

No. There is currently no therapeutically equivalent version of Invanz available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Invanz. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Carbapenem antibiotic
    Patent 5,952,323
    Issued: September 14, 1999
    Inventor(s): Zimmerman; Jeffrey A. & Williams; John M. & Bergquist; Paul A. & DiMichele; Lisa M. & DuBost; David C. & Kaufman; Michael J. & Sidler; Daniel R. & Hunke; William A.
    Assignee(s): Merck & Co., Inc.
    A pharmaceutical composition is disclosed which contains a compound of formula I: ##STR1## or a pharmaceutically acceptable salt, prodrug or hydrate thereof, in the stabilized form and/or in combination with a carbon dioxide source.
    Patent expiration dates:
    • May 15, 2017
      Drug product
    • November 15, 2017
      Pediatric exclusivity
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.